Compare Aecom (ACM) vs Moderna, Inc. (MRNA) Price & Performance

ACM's stock declined 15.32% to $62.07, driven by a Q2 2026 earnings miss with a loss of $0.50 per share versus a $1.46 estimate, alongside a securities fraud investigation announcement (Business Wire, August 11, 2026). Technical indicators are bearish, with support at $62. Despite this, revenue reached $16.14 billion in 2025, and analyst consensus remains positive with a $88.25 price target and 64% buy ratings.

The outlook is mixed: strong fundamentals like a low P/S of 0.57 and record backlog offer upside, but near-term risks from project delays and legal scrutiny may pressure the stock. Earnings volatility and negative ROE/ROA highlight execution challenges, requiring careful monitoring of quarterly results and legal developments for investor confidence.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.